<DOC>
	<DOCNO>NCT01400633</DOCNO>
	<brief_summary>The purpose study investigate overall response rate ( ORR ) safety treat patient myelodysplastic syndrome decitabine . Decitabine administer long evidence clinical benefit .</brief_summary>
	<brief_title>An Observational Study Dacogen Long-Term Treatment Patients With Myelodysplastic Syndrome</brief_title>
	<detailed_description>This study prospective ( study follow group individual time ) , open label ( people involve know identity intervention ) , multicenter , single arm ( one group patient receive treatment ) , observational study observe response rate safety decitabine treat patient myelodysplastic syndrome decitabine . Decitabine administer long evidence clinical benefit . It assess treatment duration could prolong appropriate toxicity management active antibiotic prophylaxis dose schedule modification , whether lead potentially increase clinical benefit high response rate , long time Acute Myeloid Leukemia , prolong overall survival . For safety evaluation , adverse event peripheral blood finding collect . The patient receive decitabine intravenous injection 20mg/m2 day 5 consecutive day every 4 week .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Patients diagnose ( primary secondary ) Myelodysplastic Syndrome include Chronic Myelomonocytic Leukemia ( CMML ) Patients International Prognostic Scoring System &gt; = Int1 Patients never treat hypomethylating agent ( azacitidine decitabine ) Female patient postmenopausal receive contraceptive operation refrain sexual relation . Women childbearing potential conduct effective method birth control ( oral contraceptive , injection , intrauterine device , double barrier method , contraceptive patch male partner 's sterilization ) , case male patient baby within 2 month completion decitabine therapy Patients sign informed consent document indicate understand purpose procedure require study willing participate study . Patients diagnose Acute Myelogenous Leukemia ( AML , bone marrow stem cell count exceed 20 % ) progressive malignant diseases Patients active infection virus bacteria Patients use treated azacitidine decitabine Patients hypersensitive excipients decitabine Patients pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>Dacogen</keyword>
	<keyword>decitabine</keyword>
	<keyword>epigenetic therapy</keyword>
	<keyword>hypomethylating agent</keyword>
</DOC>